These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 32006646)

  • 21. Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study.
    Davis G; Bailey R; Calhoun P; Price D; Beck RW
    Diabetes Technol Ther; 2022 May; 24(5):324-331. PubMed ID: 34962151
    [No Abstract]   [Full Text] [Related]  

  • 22. Socioeconomic status and time in glucose target range in people with type 2 diabetes: a baseline analysis of the GP-OSMOTIC study.
    Tan ML; Manski-Nankervis JA; Thuraisingam S; Jenkins A; O'Neal D; Furler J
    BMC Endocr Disord; 2018 Jul; 18(1):47. PubMed ID: 30031385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between daily and visit-to-visit glycemic variability in patients with type 2 diabetes.
    Tsuchiya T; Saisho Y; Murakami R; Watanabe Y; Inaishi J; Itoh H
    Endocr J; 2020 Aug; 67(8):877-881. PubMed ID: 32389920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a novel continuous glucose monitoring-based method for mealtime insulin dosing--the iBolus--in subjects with type 1 diabetes using continuous subcutaneous insulin infusion therapy: a randomized controlled trial.
    Rossetti P; Ampudia-Blasco FJ; Laguna A; Revert A; Vehì J; Ascaso JF; Bondia J
    Diabetes Technol Ther; 2012 Nov; 14(11):1043-52. PubMed ID: 23003329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defining the target value of the coefficient of variation by continuous glucose monitoring in Chinese people with diabetes.
    Mo Y; Ma X; Lu J; Shen Y; Wang Y; Zhang L; Lu W; Zhu W; Bao Y; Zhou J
    J Diabetes Investig; 2021 Jun; 12(6):1025-1034. PubMed ID: 33119969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system.
    Li LQ; Yao MY; Ma JX; Xue P; Li YK
    Endocr J; 2019 Oct; 66(10):871-880. PubMed ID: 31243192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment.
    Miya A; Nakamura A; Handa T; Nomoto H; Kameda H; Cho KY; Nagai S; Miyoshi H; Atsumi T
    J Diabetes Investig; 2021 May; 12(5):738-746. PubMed ID: 33021063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HBA1C AND MEAN GLUCOSE DERIVED FROM SHORT-TERM CONTINUOUS GLUCOSE MONITORING ASSESSMENT DO NOT CORRELATE IN PATIENTS WITH HBA1C >8.
    Yamada E; Okada S; Nakajima Y; Bastie CC; Vatish M; Tagaya Y; Osaki A; Shimoda Y; Shibusawa R; Saito T; Okamura T; Ozawa A; Yamada M
    Endocr Pract; 2017 Jan; 23(1):10-16. PubMed ID: 27631849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Macronutrient Intake and Number of Meals on Glycemic Outcomes Over 1 Year in Youth with Type 1 Diabetes.
    Ortiz La Banca Barber R; Volkening LK; Mehta SN; Dassau E; Laffel LM
    Diabetes Technol Ther; 2024 Jun; 26(6):420-425. PubMed ID: 38277162
    [No Abstract]   [Full Text] [Related]  

  • 30. Translating glycated hemoglobin A1c into time spent in glucose target range: A multicenter study.
    Petersson J; Åkesson K; Sundberg F; Särnblad S
    Pediatr Diabetes; 2019 May; 20(3):339-344. PubMed ID: 30652407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations between improved glucose control and patient-reported outcomes after initiation of insulin pump therapy in patients with type 2 diabetes mellitus.
    Peyrot M; Rubin RR; Chen X; Frias JP
    Diabetes Technol Ther; 2011 Apr; 13(4):471-6. PubMed ID: 21355725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time spent in target range assessed by self-monitoring blood glucose associates with glycated hemoglobin in insulin treated patients with diabetes.
    Cutruzzolà A; Irace C; Parise M; Fiorentino R; Pio Tripodi PF; Ungaro S; Babinsky V; Gnasso A
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1800-1805. PubMed ID: 32669240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose.
    Su JB; Wang XQ; Chen JF; Wu G; Jin Y
    Chin Med J (Engl); 2011 Jan; 124(1):144-7. PubMed ID: 21362322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Importance of Continuous Glucose Monitoring-derived Metrics Beyond HbA1c for Optimal Individualized Glycemic Control.
    Yoshii H; Mita T; Katakami N; Okada Y; Osonoi T; Aso K; Kurozumi A; Wakasugi S; Sato F; Ishii R; Gosho M; Shimomura I; Watada H
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e3990-e4003. PubMed ID: 35908248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry.
    Sandig D; Grimsmann J; Reinauer C; Melmer A; Zimny S; Müller-Korbsch M; Forestier N; Zeyfang A; Bramlage P; Danne T; Meissner T; Holl RW
    Diabetes Technol Ther; 2020 Aug; 22(8):602-612. PubMed ID: 32522039
    [No Abstract]   [Full Text] [Related]  

  • 36. Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study.
    Kuroda N; Kusunoki Y; Osugi K; Ohigashi M; Azuma D; Ikeda H; Makino S; Otsuka A; Tamada D; Watanabe N; Washio K; Tsunoda T; Matsuo T; Konishi K; Katsuno T; Koyama H;
    J Diabetes Investig; 2021 Feb; 12(2):244-253. PubMed ID: 32594655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term glycemic control and glucose variability assessed with continuous glucose monitoring in a pediatric population with type 1 diabetes: Determination of optimal sampling duration.
    Piona C; Marigliano M; Mozzillo E; Franzese A; Zanfardino A; Iafusco D; Maltoni G; Zucchini S; Delvecchio M; Maffeis C
    Pediatr Diabetes; 2020 Dec; 21(8):1485-1492. PubMed ID: 32935887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimation of Hemoglobin A1c from Continuous Glucose Monitoring Data in Individuals with Type 1 Diabetes: Is Time In Range All We Need?
    Fabris C; Heinemann L; Beck R; Cobelli C; Kovatchev B
    Diabetes Technol Ther; 2020 Jul; 22(7):501-508. PubMed ID: 32459124
    [No Abstract]   [Full Text] [Related]  

  • 39. Glycemic Metrics Derived From Intermittently Scanned Continuous Glucose Monitoring.
    Hansen KW; Bibby BM
    J Diabetes Sci Technol; 2022 Jan; 16(1):113-119. PubMed ID: 33269634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of short-term iPRO continuous glucose monitoring on hemoglobin A1c levels in clinical practice.
    Pepper GM; Steinsapir J; Reynolds K
    Diabetes Technol Ther; 2012 Aug; 14(8):654-7. PubMed ID: 22690923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.